Portfolio PR – Sound Bioventures

All Events Fund articles Fund PR Portfolio articles Portfolio PR

Read about Artax Biopharma and their journey developing a revolutionary therapy for autoimmune diseases that makes a meaningful difference in patients lives.

Artax Biopharma to present on first-in-class Nck modulator at the 2025 AAD Annual Meeting

2025.03.032025.03.03 / Poster presentation on evaluation of Nck modulator in atopic dermatitis models Cambridge, MA, March 3, 2025 – Artax Biopharma, Inc., a clinical-stage biotechnology company focused on tran ...

AnaCardio reports first patient dosed in the phase 2a study evaluating AC01 in patients with heart failure and reduced ejection fraction (HFrEF)

2025.02.272025.02.27 / February 25, 2025, Stockholm, Sweden - AnaCardio, a clinical-stage biopharmaceutical company developing novel contractile agents to treat patients with heart failure today announced that the first pa ...

Read about Artax Biopharma and their journey developing a revolutionary therapy for autoimmune diseases that makes a meaningful difference in patients lives.

Artax Biopharma achieves clinical validation of first-in-class, oral, Nck modulator AX-158 for autoimmune disease in phase 2a study

2025.01.22 / Novel breakthrough: first molecule to modulate the fundamental mechanism ofT cell activation underlying autoimmune pathology Statistically significant improvements in T cell and psoriasis-related ...

Theolytics Appoints David Apelian MD, PhD, MBA as CEO

2024.12.172024.12.17 / David Apelian MD PhD MBA, an experienced CEO with significant development and regulatory experience in virology and immune-oncology joins Theolytics Dr Apelian joins as the company advances its f ...

Theolytics Doses First Patient in Phase I/IIa Trial of THEO-260 in Ovarian Cancer

2024.11.192024.11.19 / THEO-260 lyses cancer cells and cancer associated fibroblasts whilst alleviating immune suppression in preclinical studies. THEO-260 is a mechanistically novel oncolytic immunotherapy developed to ...

VarmX announces appointment of John Glasspool as CEO

2024.11.122024.11.12 / Leadership team fully strengthened to drive next phase of development Leiden, The Netherlands, 12 november 2024 VarmX, a biotech company developing innovative approaches for the bypass of direc ...

ARTHEx biotech

ARTHEx Biotech Announces First Patient Dosed in Phase I-IIa ArthemiR™ Trial for Myotonic Dystrophy Type 1 (DM1)

2024.10.212024.10.21 / VALENCIA, Spain, Oct. 18, 2024 /PRNewswire/ -- ARTHEx Biotech S.L., a clinical-stage biotechnology company focused on developing innovative medicines through the modulation of gene expressi ...

Read about Artax Biopharma and their journey developing a revolutionary therapy for autoimmune diseases that makes a meaningful difference in patients lives.

Artax Biopharma completes patient recruitment in Phase 2a trial with first-in-class Nck modulator AX-158

2024.08.132024.09.09 / AX-158 has broad potential to treat many autoimmune diseases without causing immunosuppression Psoriasis biomarker panel and PASI scores expected later this year Cambridge, MA, August 13, 2024 ...

NephroDI Therapeutics Announces Investment by Sound Bioventures to Accelerate Development of NDI-5001 as a Potential First-in-Class Therapy for Pediatric Orphan Kidney Disease

2024.06.202024.09.04 / New funding to take NDI-5001 into and through clinical proof of concept in Congenital Nephrogenic Diabetes Insipidus (NDI) New investment complements previously announced strategic corporate part ...

ARTHEx biotech

ARTHEx Biotech Receives IND Clearance from FDA to Initiate the Phase I-IIa ArthemiR™ Trial of ATX-01 for Myotonic Dystrophy Type 1 (DM1)

2024.02.282024.05.13 / -ATX-01 is the industry’s first microRNA therapeutic to be evaluated for DM1 and the first program from ARTHEX’s pipeline to enter the clinic – -First patient expected to be enrolled in Q2 2024- ...

Artax Announces First Patient Dosed in Phase 2a Psoriasis Trial Evaluating AX-158.

2024.02.132024.05.13 / Safety and Efficacy Results Are Expected in Second Half of 2024 Evaluating AX-158, a First in Class Nck Blocker, Shifting the Paradigm of Autoimmune Disease Treatment. AX-158 Has Broad Poten ...

Breye Therapeutics Commences Oral Dosing of Danegaptide in Patients with Diabetic Retinopathy

2024.01.252024.05.13 / • Investigating potential for an oral treatment in diabetic retinopathy• First patient dosed in Phase 1b/2a clinical trial Copenhagen, Denmark, 25 January 2024 – Breye Therapeutics ApS (Breye), a ...